EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma

Honghui Zhu, Qi Lin, Zhixian Yu, Xixi Huang

Frontiers in Pharmacology · 03.06.2026 · 17

DOI: 10.3389/fphar.2026.1838896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.06.2026. Verfasst von Honghui Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antihypertensive drug targets are associated with various cancers, but their relationship with clear cell renal cell carcinoma (CCRCC) risk remains unclear.

Methods

Summary-data-based Mendelian randomization (SMR) and colocalization analyses were performed. Four antihypertensive drug targets (ACE, ADRB1, ADRB2, and SLC12A3) and CCRCC were included. Patients with CCRCC were identified from two large GWAS databases, including 752,817 and 315,137 individuals (Finnish cohorts), for the discovery and external validation analyses, respectively. Meta-analysis was conducted to integrate the results from both cohorts. Western blotting and prognostic analyses of tumor survival revealed the relationship between ADRB1 and CCRCC.

Results

ADRB1 was associated with CCRCC risk in both the discovery and validation cohorts (odds ratio (OR): 1.097, per standard deviation unit (SD) change in antihypertensive drug target perturbation equivalent to 1 SD unit of decreased blood pressure; 95% confidence interval (95% CI): 1.063–1.132; P-value = 0.016) vs. OR: 1.284; 95% CI: 1.014–1.627; P-value = 0.013). ADRB2 was associated with CCRCC risk in discovery cohort (OR: 1.224; 95% CI: 1.045–1.433; P-value = 0.019). Integrated outcomes demonstrated that both ADRB1 (OR: 1.100; 95% CI: 1.066–1.135; P-value<0.0001) and ADRB2 (OR: 1.313; 95% CI: 1.137–1.517; P-value = 0.0002) were associated with CCRCC risk. Colocalization analyses indicated that ADRB1 (PP4 = 0.996) and ADRB2 (PP4 = 0.895) shared the same region of genetic variation with CCRCC. Furthermore, ADRB1 was highly expressed in CCRCC tumor tissues and was associated with poor tumor survival and prognosis.

Conclusion

ADRB1 was associated with the risk of CCRCC, providing additional perspectives into potential treatment strategies for CCRCC.

Schlagwörter

Stichwörter der Autor:innen

antihypertensive drug targetsclear cell renal cell carcinoma riskcolocalization analysisgenetic variantsmendelian randomization

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Zitieren

APA

Zhu, H., Lin, Q., Yu, Z., & Huang, X. (2026). Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1838896

Vancouver

Zhu H, Lin Q, Yu Z, Huang X. Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1838896

BibTeX
@article{Zhu2026,
  author = {Zhu, Honghui and Lin, Qi and Yu, Zhixian and Huang, Xixi},
  title = {Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1838896}
}
Kostenlos starten →